Global Information
회사소개 | 문의 | 비교리스트

로타바이러스 감염증 : 파이프라인 리뷰

Rotavirus Infections - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 251575
페이지 정보 영문 55 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


로타바이러스 감염증 : 파이프라인 리뷰 Rotavirus Infections - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 55 Pages

로타바이러스는 장을 오염시키는 바이러스이며, 유아나 어린이에서 볼 수 있는 심한 설사의 가장 일반적인 원인입니다. 로타바이러스는 간혹 대변-구강 경로를 통해 감염됩니다. 일반적으로 손을 잘 씻지 않거나 오염된 식품과 물을 섭취하여 발생합니다. 바이러스는 호흡기를 통해서나 다른 체액에 의해 전염될 수 있지만 그러한 경우는 그다지 많지 않습니다. 바이러스는 무생물 표면(예를 들면 문 손잡이, 장난감, 경표면)에 있는 경우도 있습니다. 증상으로는 심한 설사, 구토, 발열, 탈수 등이 있습니다.

로타바이러스 감염증(Rotavirus Infections) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업이나 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최신 뉴스 및 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

로타바이러스 감염증 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기어별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

로타바이러스 감염증 치료제 개발 참여 기업

  • Beijing Minhai Biotechnology Co Ltd
  • Bharat Biotech International Ltd
  • Biological E Ltd
  • Curevac AG
  • Medicago Inc
  • Nanotherapeutics Inc
  • Serum Institute of India Ltd
  • Shantha Biotechnics Ltd
  • Takeda Pharmaceutical Company Ltd
  • Wuhan Institute of Biological Products Co Ltd

약제 개요

로타바이러스 감염증 : 휴지중인 프로젝트

로타바이러스 감염증 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.06.12

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Rotavirus Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Rotavirus Infections - Pipeline by Aridis Pharmaceuticals Inc, H1 2020
  • Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Rotavirus Infections - Pipeline by Bharat Biotech Ltd, H1 2020
  • Rotavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
  • Rotavirus Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Rotavirus Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H1 2020
  • Rotavirus Infections - Pipeline by Medicago Inc, H1 2020
  • Rotavirus Infections - Pipeline by Micron Biomedical Inc, H1 2020
  • Rotavirus Infections - Pipeline by Pfizer Inc, H1 2020
  • Rotavirus Infections - Pipeline by Serum Institute of India Ltd, H1 2020
  • Rotavirus Infections - Pipeline by UMN Pharma Inc, H1 2020
  • Rotavirus Infections - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
  • Rotavirus Infections - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Rotavirus Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.

Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical, Discovery and Unknown stages comprises 1, 3, 1, 1 and 1 molecules, respectively.

Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rotavirus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rotavirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rotavirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rotavirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rotavirus Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rotavirus Infections - Overview
    • Rotavirus Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Rotavirus Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rotavirus Infections - Companies Involved in Therapeutics Development
    • Aridis Pharmaceuticals Inc
    • Beijing Minhai Biotechnology Co Ltd
    • Bharat Biotech Ltd
    • Chongqing Zhifei Biological Products Co Ltd
    • GlaxoSmithKline Plc
    • Hilleman Laboratories Pvt Ltd
    • Medicago Inc
    • Micron Biomedical Inc
    • Pfizer Inc
    • Serum Institute of India Ltd
    • UMN Pharma Inc
    • Yisheng Biopharma Co Ltd
  • Rotavirus Infections - Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (rotavirus (virus like particle) + typhiod) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDG-5625 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • poliomyelitis vaccine + rotavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rotavac-5C - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus [Serotype P2-VP8] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus [serotypes A1, A2, A3, A4] (tetravalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus [serotypes G1, G2, G3, G4, P1(8)] (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rotavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RV-3BB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RV-625 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UMN-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rotavirus Infections - Dormant Projects
  • Rotavirus Infections - Product Development Milestones
    • Featured News & Press Releases
      • Jun 03, 2019: Rotavirus vaccine (Rotarix): patient group direction (PGD) template
      • Jan 24, 2018: India-made rotavirus vaccine achieves World Health Organization prequalification
      • Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus
      • Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate
      • Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus
      • Apr 26, 2012: GSK's Rotarix To Be Introduced In Ghana
      • Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan
      • May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix
      • Oct 15, 1999: Wyeth Lederle Vaccines Voluntarily Withdraws from the Market its Rotavirus Vaccine RotaShield
      • Aug 31, 1998: Wyeth-Ayerst Receives FDA Licensure for RotaShield; First Vaccine for Use in the Prevention of Rotavirus
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q